Targacept to Report First Quarter 2011 Financial Results on May 5, 2011

WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it will report financial results for the first quarter on Thursday, May 5, 2011, after the U.S. financial markets close.

Management will discuss the first quarter financial results, provide an update on the company’s product development programs and business activities, and discuss expectations for the future via conference call at 5:00 p.m. Eastern Time on Thursday, May 5, 2011. The conference call may be accessed by dialing (866) 202-3048 for domestic participants and (617) 213-8843 for international callers (reference passcode 13322530). A replay of the conference call may be accessed from approximately 8:00 p.m. Eastern Time on May 5, 2011 through May 19, 2011 by dialing (888) 286-8010 for domestic callers and (617) 801-6888 for international callers (reference passcode 29298238).

A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with AstraZeneca and is in Phase 3 clinical studies as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.

TARGACEPT
Building Health, Restoring Independence(SM)



CONTACT:

Targacept, Inc.
Alan Musso, SVP, Finance and Administration and CFO
336-480-2186, [email protected]
or
Linnden Communications
Michelle Linn, 508-362-3087, [email protected]

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.